Friday, July 10, 2026

pharma · Prurigo Nodularis · Vitiligo

Incyte

Incyte clinical programs — 53 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

1801 Augustine Cut-Off, Wilmington, Delaware 19803, US HQ
3,381 Employees
NMPA registrant Type
Company details
Status
Public
HQ
1801 Augustine Cut-Off, Wilmington, Delaware 19803, US
Employees
3,381
Programs
53
Drugs
61
Patents
0
Intelligence · Clinical Programs

Incyte projects

53 ClinicalTrials.gov programs sponsored by Incyte.

Incyte has 53 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

Page 2 of 2
  1. INCB 81776-101

    Incyte

    Advanced malignancies.

    phase 1 other active

    1 trial
  2. INCB 99280-205

    Incyte

    Solid tumor

    phase 1 small molecule active

    1 trial
  3. INCB099280

    Incyte

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial
  4. INCB160058-101

    Incyte

    Myeloproliferative Neoplasms

    phase 1 other active

    1 trial
  5. Itacitinib

    Incyte

    Acute Graft-versus-host Disease

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Incyte have?

53 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.